Seattle, WA, February 23-26, 2015
Exciting results from many studies in Pre-Exposure Prophylaxis, HIV and hepatitis C were presented at this year’s Conference on Retroviruses and Opportunistic Infections. For complete coverage by Project Inform from the 2015 CROI, read the March 2015 issue of PI Perspective, or click on the various articles below.
HIV CURE NEWS
New “Kick and Kill” HIV cure drug (TLR7 agonist) from Gilead shows promise
HIV PREVENTION NEWS
Daily PrEP reduces HIV infections by 86% in U.K. PROUD Study
Sex-based PrEP cuts infections by 86%
HIV DRUG DEVELOPMENT NEWS
New form of tenofovir TAF looks to be easier on bone and kidney health to the current TDF
HIV maintenance regimen of cabotegravir and rilpivirine looks promising
New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat
HIV CARE NEWS
Starting HIV treatment early leads to better health and improved immune systems
Using raltegravir or protease inhibitors influences about equal levels of fat gains
BREATHER Study’s novel dosing regimen of 5 days on/2 days off controls HIV levels in young people
Dutch ATHENA study announces surprising results when using 3TC (lamivudine) over FTC (emtricitabine)
The risk for transmission persists through the first six months of HIV treatment
Smoking greatly increases risk for non-AIDS cancers in people with HIV
Contraceptive implant levorongestrel may not be as effective when taking efavirenz (Sustiva)
Financial incentives don’t increase case linkage or viral suppression
HEPATITIS C NEWS
Adherence to a once-daily medication in hepatitis C mono-infected and HIV/HCV co-infected patients
High SVR rates in HIV/HCV co-infected patients with a fixed-dose regimen of ledipasvir/sofosbuvir
HCV transmission risk factors in HIV-infected MSM
High SVR12 rates seen in HIV/HCV co-infected persons who take daclatasvir with sofosbuvir
The benefits of achieving SVR in HCV mono-Infected and HIV/HCV co-infected persons